JMI LABS IS NOW PART OF LEARN MORE

Filter by Category: Medical Writing

Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates.

Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. by Streit JM, Fritsche TR, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2004; 48 (2): 137-143

Commercial broth microdilution panel validation and reproducibility trials for NVP PDF-713 (LBM415), a novel inhibitor of bacterial peptide deformylase.

Commercial broth microdilution panel validation and reproducibility trials for NVP PDF-713 (LBM415), a novel inhibitor of bacterial peptide deformylase. by Fritsche TR, Moet GJ, Jones RN published in Clin. Microbiol. Infect. 2004; 10 (9): 857-860

Disk diffusion quality control guidelines for NVP PDF-713: A novel peptide deformylase inhibitor.

Disk diffusion quality control guidelines for NVP PDF-713: A novel peptide deformylase inhibitor. by Anderegg TR, Jones RN, The Quality Control Working Group published in Diagn. Microbiol. Infect. Dis. 2004; 48 (1): 55-57

Results of two worldwide surveys into physician awareness and perceptions of extended-spectrum beta-lactamases.

Results of two worldwide surveys into physician awareness and perceptions of extended-spectrum beta-lactamases. by Goossens H, Malhotra-Kumar S, Eraksoy H, Unal S, Grabein B, Masterton R, Mendes C, Garcia-Rodriguez J-A, Russo G and Jones RN published in Clin. Microbiol. Infect. 2004; 10 (8):760-762

Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide.

Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide. by Jones RN, Streit JM and Fritsche TR published in Int. J. Antimicrob. Agents. 2004; 23 (2): 197-199

Potency and spectrum reevaluation of cefdinir tested against pathogens Causing skin and soft tissue infections: A sample of North American isolates.

Potency and spectrum reevaluation of cefdinir tested against pathogens causing skin and soft tissue infections: A sample of North American isolates. by Sader HS, Streit JM, Fritsche TR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2004; 49 (4): 283-287

Preliminary susceptibility testing guidelines for AZD2563, a long-acting oxazolidinone.

Preliminary susceptibility testing guidelines for AZD2563, a long-acting oxazolidinone. by Anderegg TR and Jones RN published in Int. J. Antimicrob. Agents 2004; 23 (1): 6-10

Activities of doripenem (S-4661) against drug-resistant clinical pathogens.

Activities of doripenem (S-4661) against drug-resistant clinical pathogens. by Jones RN, Huynh HK, Biedenbach DJ published in Antimicrob. Agents. Chemother. 2004; 48 (8): 3136-3140

Does the use of antibiotics in food animals pose a risk to human health? A critical review of published data.

Does the use of antibiotics in food animals pose a risk to human health? A critical review of published data. by Phillips I, Casewell M, Cox T, De Groot B, Friis C, Jones RN, Nightingale C, Preston R, Waddell J published in J. Antimicrob. Chemother. 2004; 53 (1): 28-52

Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.

Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. by Jones RN, Huynh HK, Biedenbach DJ, Fritsche TR, Sader HS published in J. Antimicrob. Chemother. 2004; 54 (1): 144-154

Emergence of two Klebsiella pneumoniae isolates harboring plasmid-mediated CTX-M-15 beta-lactamase in Taiwan.

Emergence of two Klebsiella pneumoniae isolates harboring plasmid-mediated CTX-M-15 beta-lactamase in Taiwan. by Yu W-L, Wu L-T, Pfaller MA, Winokur PL and Jones RN published in Antimicrob. Agents Chemother. 2004; 48 (1): 362-363

Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: Spectrum of antimicrobial activity and measurements of bactericidal activity.

Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: Spectrum of antimicrobial activity and measurements of bactericidal activity. by Sader HS, Fedler KA, Rennie RP, Stevens S and Jones RN published in Antimicrob. Agents Chemother. 2004; 48 (8): 3112-3118

Does the use of antibiotics in food animals pose a risk to human health? A reply to critics.

Does the use of antibiotics in food animals pose a risk to human health? A reply to critics. by Phillips I, Casewell M, Cox T, de Groot B, Friis C, Jones R, Nightingale C, Preston R, Waddell J published in J. Antimicrob. Chemother. 2004; 54 (1): 276-278

Development of a standardized susceptibility test for Campylobacter with quality control ranges for ciprofloxacin, doxycycline, erythromycin, gentamicin, and meropenem.

Development of a standardized susceptibility test for Campylobacter with quality control ranges for ciprofloxacin, doxycycline, erythromycin, gentamicin, and meropenem. by McDermott P, Bodeis S, Aarestrup F, Brown S, Traczewski M, Fedorka-Cray P, Wallace M, Critchley I, Thornsberry C, Graff S, Flamm R, Beyer J, Shortridge D, Piddock L, Ricci V, Johnson M, Jones R, Reller B, Mirrett S, Aldrobi J, Rennie R, Brosnikoff C published in Microbial. Drug Resist. 2004; 10 (2): 124-131

Quality control guidelines for BAL9141 (RO 63-9141), an investigational cephalosporin, when reference MIC and standardized disk diffusion susceptibility test methods are used.

Quality control guidelines for BAL9141 (RO 63-9141), an investigational cephalosporin, when reference MIC and standardized disk diffusion susceptibility test methods are used. by Anderegg TR, Jones RN and Sader HS published in J. Clin. Microbiol. 2004; 42 (7): 3356-3358

Antibiotic use in animals.

Antibiotic use in animals. by Phillips I, Casewell M, Cox T, DeGroot B, Friis C, Jones RN, Nightingale C, Preston R, Waddell J published in J. Antimicrob. Chemother. 2004; 53 (5): 885

Public health consequences of macrolide use in food animals: A deterministic risk assessment.

Public health consequences of macrolide use in food animals: A deterministic risk assessment. by Hurd HS, Doores S, Hayes D, Mathew A, Maurer J, Silley P, Singer RS and Jones RN published in J. Food Protect. 2004; 67 (5): 980-992

Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis.

Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis. by Ambrose PG, Anon JB, Owen JS, Van Wart S, McPhee ME, Bhavnani SM, Piedmonte M and Jones RN published in Clin. Infect. Dis. 2004; 38 (11): 1513-1520

Antagonism between penicillin and erythromycin against Streptococcus pneumoniae: Does it exist?

Antagonism between penicillin and erythromycin against Streptococcus pneumoniae: Does it exist? by Deshpande LM, Jones RN published in Diagn. Microbiol. Infect. Dis. 2003; 46 (3): 223-225

Cloning of a hybrid metallo-beta-lactamase gene conferring a novel IMP variant blaIMP-13 in Pseudomonas aeruginosa in Italy: Report from the SENTRY Antimicrobial Surveillance Program.

Cloning of a hybrid metallo-beta-lactamase gene conferring a novel IMP variant blaIMP-13 in Pseudomonas aeruginosa in Italy: Report from the SENTRY Antimicrobial Surveillance Program by Toleman MA, Jones RN, Walsh TR published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1): 119

Commercial broth microdilution panel validation and reproducibility trials for garenoxacin (BMS-284756), a novel desfluoroquinolone.

Commercial broth microdilution panel validation and reproducibility trials for garenoxacin (BMS-284756), a novel desfluoroquinolone. by Gordon KA, Rhomberg PR, Jones RN published in J. Clin. Microbiol. 2003; 41 (8): 3967-3969

Confirmation of extended-spectrum ß-lactamase-producing Serratia marcescens: Preliminary report from Taiwan.

Confirmation of extended-spectrum ß-lactamase-producing Serratia marcescens: Preliminary report from Taiwan. by Yu WL, Wu LT, Pfaller MA, Winokur PL, Jones RN published in Diagn. Microbiol. Infect. Dis. 2003; 45 (4): 221-224

Relationships between patient- and institution-specific variables and decreased antimicrobial susceptibility of Gram-negative pathogens.

Relationships between patient- and institution-specific variables and decreased antimicrobial susceptibility of Gram-negative pathogens. by Bhavnani SM, Hammel JP, Forrest A, Jones RN and Ambrose PG published in Clin. Infect. Dis. 2003; 37 (3): 344-350

Biochemical characterization of the acquired metallo-beta-lactamase SPM-1 from Pseudomonas aeruginosa.

Biochemical characterization of the acquired metallo-beta-lactamase SPM-1 from Pseudomonas aeruginosa. by Murphy TA, Simm AM, Toleman MA, Jones RN and Walsh TR published in Antimicrob. Agents Chemother. 2003; 47 (2): 582-587

Validation of commercial dry-form broth microdilution panels for susceptibility testing of AZD2563, a new long-acting oxazolidinone.

Validation of commercial dry-form broth microdilution panels for susceptibility testing of AZD2563, a new long-acting oxazolidinone. by Jones RN, Anderegg TR and Biedenbach DJ published in Clin. Microbiol. Infect. 2003; 9 (6): 543-546

Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitor.

Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitor. by Jones RN, Rhomberg PR published in J. Antimicrob. Chemother. 2003; 51 (1): 157-161

Quality control guidelines for MIC susceptibility testing of NVP PDF-713: A novel peptide deformylase inhibitor.

Quality control guidelines for MIC susceptibility testing of NVP PDF-713: A novel peptide deformylase inhibitor. by Anderegg TR, Biedenbach DJ, Jones RN and The Quality Control Working Group published in Int. J. Antimicrob. Agents 2003; 22 (1): 84-86

Emergence of an IMP-Like metallo-enzyme in an Acinetobacter baumannii clinical strain from a Brazilian teaching hospital.

Emergence of an IMP-Like metallo-enzyme in an Acinetobacter baumannii clinical strain from a Brazilian teaching hospital. by Gales AC, Tognim MCB, Reis AO, Jones RN, Sader HS published in Diagn. Microbiol. Infect. Dis. 2003; 45 (1): 77-79

Re-evaluation of quality control guidelines for gatifloxacin and garenoxacin (BMS284756) when susceptibility testing Haemophilus influenzaeStreptococcus pneumoniae.

Re-evaluation of quality control guidelines for gatifloxacin and garenoxacin (BMS284756) when susceptibility testing Haemophilus influenzae and Streptococcus pneumoniae. by Anderegg TR, Biedenbach DJ, Jones RN and The Quality Control Working Group published in Diagn. Microbiol. Infect. Dis. 1996; 46: 147-150

Determination of disk diffusion and MIC quality control parameters for AZD2563, a novel long-acting oxazolidinone.

Determination of disk diffusion and MIC quality control parameters for AZD2563, a novel long-acting oxazolidinone. by Anderegg TR, Jones RN, The Quality Control Study Group published in Diagn. Microbiol. Infect. Dis. 2003; 45 (1): 73-76

Initial quality control evaluations for susceptibility testing of dalbavancin (BI397), an investigational glycopeptide with potent Gram-positive activity.

Initial quality control evaluations for susceptibility testing of dalbavancin (BI397), an investigational glycopeptide with potent Gram-positive activity. by Anderegg TR, Biedenbach DJ, Jones RN and The Quality Control Working Group published in J. Clin. Microbiol. 2003; 41 (6): 2795-2796

Characterization of heteroresistance to fluconazole among clinical isolates of Cryptococcus neoformans.

Characterization of heteroresistance to fluconazole among clinical isolates of Cryptococcus neoformans. by Yamazumi T, Pfaller MA, Messer SA, Houston AK, Boyken L, Hollis RJ, Furuta I, Jones RN published in J. Clin. Microbiol. 2003; 41 (1): 267-272

Initial disk diffusion quality control guidelines for tylosin tested against Staphylococcus aureus ATCC 25923 and Streptococcus pneumoniae ATCC 49619.

Initial disk diffusion quality control guidelines for tylosin tested against Staphylococcus aureus ATCC 25923 and Streptococcus pneumoniae ATCC 49619. by Anderegg TR, Jones RN and The Quality Control Working Group published in Int. J. Antimicrob. Agents 2003; 21 (6): 594-596

Results of the survey of the quality assurance for commercially prepared microbiology media. Update from the College of American Pathologists Microbiology Surveys Program (2001).

Results of the survey of the quality assurance for commercially prepared microbiology media. Update from the College of American Pathologists Microbiology Surveys Program (2001). by Jones RN, Krisher K, Bird DS and CAP Microbiology Resource Committee published in Arch. Pathol. Lab. Med. 2003; 127 (6): 661-665

Initial description of the L22 mutation responsible for quinupristin/dalfopristin resistance in Streptococcus pneumoniae: Case reports from the SENTRY Antimicrobial Surveillance Program. Abstr. P1548.

Initial description of the L22 mutation responsible for quinupristin/dalfopristin resistance in Streptococcus pneumoniae: Case reports from the SENTRY Antimicrobial Surveillance Program. Abstr. P1548. by Jones RN, Farrell D, Morrissey I on Behalf of the SENTRY Participants Group published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1): 377

Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci.

Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci. by Deshpande LM and Jones RN published in Clin. Microbiol. Infect. 2003; 9 (11): 1120-1124

Contemporary activity of grepafloxacin: Re-evaluation of antimicrobial features of a potent fluoroquinolone. Abstr P1429.

Contemporary activity of grepafloxacin: Re-evaluation of antimicrobial features of a potent fluoroquinolone. Abstr. P1429. by Jones RN, Gordon KA, Rhomberg R, Fritsche TR, Sader HS published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1):346

Revision of linezolid disk diffusion quality control guidelines for testing Staphylococcus aureus ATCC 25923: An independent seven-laboratory trial.

Revision of linezolid disk diffusion quality control guidelines for testing Staphylococcus aureus ATCC 25923: An independent seven-laboratory trial. by Biedenbach DJ and Jones RN published in Clin. Microbiol. Infect. 2003; 9 (10): 1035-1037

Epidemiology and frequency of antimicrobial resistances among pathogens causing surgical site infections: Report from the SENTRY Antimicrobial Surveillance Program in the United States, Canada, and Europe.

Epidemiology and frequency of antimicrobial resistances among pathogens causing surgical site infections: Report from the SENTRY Antimicrobial Surveillance Program in the United States, Canada, and Europe. by Mathai D, Biedenbach DJ, Jones RN published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1):287-288

Antimicrobial activity of LB10827, a new orally administered cephalosporin, tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae.

Antimicrobial activity of LB10827, a new orally administered cephalosporin, tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae. by Deshpande LM, Beach ML, Mutnick AH, Jones RN published in Clin. Microbiol. Infect. 2003; 9 (8): 893-896

Comparative antimicrobial potency and spectrum of activity for meropenem and nine comparator agents: Report from the United States MYSTIC Program Surveillance Study in 2002. Abstr P1040.

Comparative antimicrobial potency and spectrum of activity for meropenem and nine comparator agents: Report from the United States MYSTIC Program Surveillance Study in 2002. Abstr P1040. by Rhomberg PR, Mutnick AH, Jones RN published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1): 243

Contemporary re-evaluation of the activity and spectrum of grepafloxacin tested against isolates in the United States.

Contemporary re-evaluation of the activity and spectrum of grepafloxacin tested against isolates in the United States. by Gordon KA, Sader HS, Jones RN published in Diagn. Microbiol. Infect. Dis. 2003; 47 (1): 377-383

Frequency of occurrence and antimicrobial susceptibility of bacterial pathogens from intensive care units in Latin American medical centers: Report from the SENTRY Antimicrobial Surveillance Program

Frequency of occurrence and antimicrobial susceptibility of bacterial pathogens from intensive care units in Latin American medical centers: Report from the SENTRY Antimicrobial Surveillance Program by Sader HS, Gales AC, Mendes RE and Jones RN on Behalf of the SENTRY Group – Latin America published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1): 226

Comparison of Streptococcus pneumoniae and Haemophilus infuenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: Five-year results for the SENTRY Antimicrobial Surveillance Program.

Comparison of Streptococcus pneumoniae and Haemophilus infuenzae,/i> susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: Five-year results for the SENTRY Antimicrobial Surveillance Program. by Gordon KA, Biedenbach DJ, Jones RN published in Diagn. Microbiol. Infect. Dis. 2003; 46 (4): 285-289

Epidemiology of the new metallo-beta-lactamase gene blaSPM, in South America: Report from the SENTRY Antimicrobial Surveillance Program. Abstr. P718.

Epidemiology of the new metallo-beta-lactamase gene blaSPM, in South America: Report from the SENTRY Antimicrobial Surveillance Program. Abstr. P718. by Toleman M, Bennett D, Walsh T, Jones RN published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1):156-157

Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum ß-lactamase in Europe.

Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum ß-Lactamase in Europe. by Jones RN, Pfaller MA and MYSTIC Study Group (Europe) published in Clin. Microbiol. Infect. 2003; 9 (7): 708-712

Evolution of an integron carrying blaVIM-2 in Central Europe: Report from the SENTRY Antimicrobial Surveillance Program. Abstr P717.

Evolution of an integron carrying blaVIM-2 in Central Europe: Report from the SENTRY Antimicrobial Surveillance Program. Abstr. P717. by Toleman MA, Hryniewicz W, Bennett P, Jones RN and Walsh TR published in Clin Microbiol Infect 2003; 9 (Suppl 1): 156

Interpretive criteria for tiamulin (DenagardTM) susceptibility testing.

Interpretive criteria for tiamulin (DenagardTM) susceptibility testing. by Walter D, Jones RN, Pfaller MA published in Proceedings of the 17th IPVS Congress, Ames, IA 2002; Vol 2: 80

Validation of commercial dry-form panels (Sensititre) for the susceptibility testing of AZD2563, a new long-acting oxazolidinone. Abstr. #P1045

Validation of commercial dry-form panels (Sensititre) for the susceptibility testing of AZD2563, a new long-Acting Oxazolidinone. Abstr. #P1045. by Jones RN, Anderegg T, Biedenbach DJ and Rhomberg P published in Clin. Microbiol. Infect. 2002; 8 (Suppl 1): 233

Intermethod agreement and preliminary quality control (QC) guidelines for susceptibility testing AZD2563 by disk diffusion and MIC methods.

Intermethod agreement and preliminary quality control (QC) guidelines for susceptibility testing AZD2563 by disk diffusion and MIC methods. by Anderegg T and Jones RN published in Clin. Microbiol. Infect. 2002; 8 (Suppl 1): 232-233